An Optimized Immunology Concept for Each Individual Patient
Duration: around 5 weeks
Cancer and the immune system are subject to dynamic processes that need to be considered during treatment. That is why the IOZK Immunotherapy is produced for each patient individually.
The IOZK Immunotherapy can be combined with other therapies, such as radio- and chemotherapy, as needed. Other than radiation or chemotherapy, which follow set protocols, the duration and components of the IOZK Immunotherapy is tailored to the individual needs of the patient.
The following course of treatment can act as a guideline to the IOZK Immunotherapy. It contains two vaccination cycles and takes around 5 weeks.
During the first consultation at the IOZK, the patient’s medical history is taken, as well as examining all existing test results and considering all possible conventional and immunological treatment options. This is followed by taking a blood sample that will be used to assess the immune system and the tumor activity. The test results are available after about two weeks.
Our team of experts meets to discuss the results and, taking into consideration the patient’s history, develops an individualized treatment plan.
Duration: 8 days
In a briefing consultation, the treatment plan is discussed with the patient. At the start of the therapy, a blood sample is taken from the patient that will be used to produce the personalized tumor vaccine IO-VAC®. The production process takes 8 days. During this time, the tumor region and the immune system are treated on an outpatient basis with modulated electrohyperthermia, administration of Newcastle Disease Virus (NDV), and, as required, a combination of vitamins and micronutrients.
On the 8th day after taking the blood sample, the first vaccination with IO-VAC® takes place.
Second Cycle of Treatment at the IOZK
Duration: 8 days
Three weeks later, another blood sample is taken for the production the second IO-VAC® vaccine. Further treatment with hyperthermia and virotherapy is administered.
On the 8th day of the second cycle, the second vaccination with IO-VAC®.
After another three weeks, an analysis of the patient’s blood provides information on the state of the immune system as well as the success of the vaccination. Using an ELISpot Test, the T cells are tested for an antitumor reaction against specific antigens. If the immune function and the T cell reaction are good, then further monitorung will be carried out at approximately three-month intervals.
Should the immune function be impaired, or if the reaction to the vaccination is decreasing, further treatment cycles with virotherapy and hyperthermia, or an additional vaccination, can be considered.
Therapy Costs
The cost for the first two treatment cycles, including diagnostics, production of IO-VAC®, and therapy amount to approximately €55,000. Depending on the terms of your health insurance, some private health insurances or employer‘s liability insurance associations contribute towards the costs.
Further Information on This Topic:
